Discover Latus’ groundbreaking gene therapy candidates, utilizing high-throughput screened AAV capsids to transform CNS disorder treatments through precision delivery. Latus’ innovative approach aims to target specific tissues, significantly enhancing safety and efficacy for patients.
Location: United States
Total raised: $151M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.05.2026 | Series A | $97M | DCVC |
| 06.05.2024 | Series A | $54M | - |
Mentions in press and media 6
| Date | Title | Description |
| 04.05.2026 | Latus Bio: $97 Million Series A Raised To Advance Gene Therapy Platform Into Larger Patient Populations | Latus Bio, a biotechnology company engineering scalable gene therapies for broader patient populations, has closed a $97 million Series A financing, including a $43 million extension led by 8VC, with participation from existing investors DC... |
| 04.05.2026 | Latus Bio Raises $97M to Expand Gene Therapy Pipeline | Latus Bio has closed a $97 million Series A financing round. The significant capital infusion is intended to accelerate the company’s clinical pipeline, specifically targeting devastating neurodegenerative conditions that have long eluded e... |
| 06.05.2024 | Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing | The funding round is being led by 8VC and DCVC Bio. To date, Samsung Life Science Fund (created by Samsung C&T, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation), The Children’s Hospital of Philadelphia Foun... |
| 03.05.2024 | Latus Bio Raises $54M in Series A Financing | Latus Bio, a Philadelphia, PA-based biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), raised $54M in Series A funding. The round was led by 8VC and DCVC Bio. To date, Samsung L... |
| - | Latus Bio: Patient-Centric And Product-Oriented Gene Therapy Company Raises $54 Million | Latus Bio, a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), announced its launch and an initial closing of $54 million in Series A funding. 8VC and DCVC Bio are leading the ... |
| - | Latus Bio | “Discover Latus’ groundbreaking gene therapy candidates, utilizing high-throughput screened AAV capsids to transform CNS disorder treatments through precision delivery. Latus’ innovative approach aims to target specific tissues, significant... |